Ontology highlight
ABSTRACT:
SUBMITTER: Loibl S
PROVIDER: S-EPMC9482917 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature
Loibl Sibylle S Huang Chiun-Sheng CS Mano Max S MS Mamounas Eleftherios P EP Geyer Charles E CE Untch Michael M Thery Jean-Christophe JC Schwaner Ingo I Limentani Steven S Loman Niklas N Lübbe Kristina K Chang Jenny C JC Hatschek Thomas T Tesarowski David D Song Chunyan C Lysbet de Haas Sanne S Boulet Thomas T Lambertini Chiara C Wolmark Norman N
NPJ breast cancer 20220919 1
Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant ...[more]